WALTHAM, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for ...
Sionna Therapeutics, Inc. (SION) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...
Shares of Sionna Therapeutics, Inc. (SION) have gained 7.9% over the past four weeks to close the last trading session at $21.62, but there could still be a solid upside left in the stock if ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results